CLINICAL_TRIALS
withdrawal
· 2014-04-07
Clinical Trial Update: LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) [Phase 4]
Summary
A Phase 4 clinical trial (LENA-LMA-5) evaluating lenalidomide in acute myeloid leukemia has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: PETHEMA Foundation | Conditions: AML | Phase 4 | Status: TERMINATED